 CAMBRIDGE, Mass., Jan. 17, 2023 GLOBE NEWSWIRE Fulcrum Therapeutics, Inc. Nasdaq: FULC, a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced the pricing of an underwritten public offering of 9,615,384 shares of its common stock at a public offering price of 13.00 per share. The ... The post Fulcrum Therapeutics Announces Pricing of Upsized Public Offering of Common Stock appeared first on ForexTV... 